Search

Your search keyword '"Strasser, Simone I."' showing total 596 results
Start Over Author "Strasser, Simone I."
596 results on '"Strasser, Simone I."'

1. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)

Author

Wigg, Alan, Tibballs, Jonathan, Woodman, Richard, Stuart, Katherine, Le, Hien, Roberts, Stuart K., Olynyk, John K., Strasser, Simone I., Wallace, Michael, Martin, Jarad, Haworth, Annette, Hardcastle, Nicholas, Loo, Kee Fong, Tang, Colin, Lee, Yoo Young, Chu, Julie, De Abreu Lourenco, Richard, Koukourou, Adam, De Boo, Diederick, McLean, Kate, Buck, Jackie, Sawhney, Rohit, Nicoll, Amanda, Dev, Anouk, Wood, Marnie, Braund, Alicia, Weltman, Martin, Khor, Richard, Levy, Miriam, Wang, Tim, Potter, Michael, Haridy, James, Raj, Ashok, Duncan, Oliver, Zekry, Amany, Collier, Natalie, O’Beirne, James, Holliday, Catherine, Trada, Yuvnik, Tronidjaja, Jaw, George, Jacob, and Pryor, David

Published
2024
Full Text
View/download PDF

2. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Author

Younossi, Zobair M, Stepanova, Maria, Noureddin, Mazen, Kowdley, Kris V, Strasser, Simone I, Kohli, Anita, Ruane, Peter, Shiffman, Mitchell L, Sheikh, Aasim, Gunn, Nadege, Caldwell, Stephen H, Huss, Ryan S, Myers, Robert P, Wong, Vincent Wai‐Sun, Alkhouri, Naim, Goodman, Zachary, and Loomba, Rohit

Subjects
Clinical Research, Digestive Diseases, Hepatitis, Chronic Liver Disease and Cirrhosis, Liver Disease, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Good Health and Well Being
Abstract

Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investigational drugs on PROs of patients with advanced nonalcoholic steatohepatitis (NASH) was investigated. Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo-controlled study of selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations (NCT03449446). PROs included Short Form 36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ)-NASH, EuroQol Five Dimension (EQ-5D), Work Productivity and Impairment (WPAI), and 5-D Itch before and during treatment. A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included. Baseline Physical Functioning (PF) and Bodily Pain of SF-36 and Fatigue and Worry of CLDQ-NASH were significantly lower in patients with cirrhosis (total CLDQ-NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P

Published
2021

3. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

Author

Clark, Paul J., Valery, Patricia C., Strasser, Simone I., Weltman, Martin, Thompson, Alexander J., Levy, Miriam, Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Published
2023
Full Text
View/download PDF

5. Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort Study

Author

Abdelmalak, Jonathan, primary, Strasser, Simone I., additional, Ngu, Natalie L., additional, Dennis, Claude, additional, Sinclair, Marie, additional, Majumdar, Avik, additional, Collins, Kate, additional, Bateman, Katherine, additional, Dev, Anouk, additional, Abasszade, Joshua H., additional, Valaydon, Zina, additional, Saitta, Daniel, additional, Gazelakis, Kathryn, additional, Byers, Susan, additional, Holmes, Jacinta, additional, Thompson, Alexander J., additional, Pandiaraja, Dhivya, additional, Bollipo, Steven, additional, Sharma, Suresh, additional, Joseph, Merlyn, additional, Sawhney, Rohit, additional, Nicoll, Amanda, additional, Batt, Nicholas, additional, Tang, Myo J., additional, Riordan, Stephen, additional, Hannah, Nicholas, additional, Haridy, James, additional, Sood, Siddharth, additional, Lam, Eileen, additional, Greenhill, Elysia, additional, Lubel, John, additional, Kemp, William, additional, Majeed, Ammar, additional, Zalcberg, John, additional, and Roberts, Stuart K., additional

Published
2024
Full Text
View/download PDF

8. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

Author

Yuen, Man-Fung, Locarnini, Stephen, Lim, Tien Huey, Strasser, Simone I., Sievert, William, Cheng, Wendy, Thompson, Alex J., Given, Bruce D., Schluep, Thomas, Hamilton, James, Biermer, Michael, Kalmeijer, Ronald, Beumont, Maria, Lenz, Oliver, De Ridder, Filip, Cloherty, Gavin, Ka-Ho Wong, Danny, Schwabe, Christian, Jackson, Kathy, Lai, Ching Lung, Gish, Robert G., and Gane, Edward

Published
2022
Full Text
View/download PDF

9. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Published
2022
Full Text
View/download PDF

10. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C).

Author

Clark, Paul J., Valery, Patricia C., Strasser, Simone I., Weltman, Martin, Thompson, Alex, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Sinclair, Marie, George, Jacob, Sievert, William, MacQuillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Cheng, Wendy, and Roberts, Stuart K.

Subjects
HEPATIC fibrosis, CHRONIC hepatitis C, ALCOHOLISM, ALCOHOL drinking, HEPATITIS C virus
Abstract

Introduction: Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct‐acting antiviral (DAA) therapy outcome and the clinical course of liver disease and 2‐year survival for patients receiving HCV DAA therapy. Methods: Adults (n = 2624) recruited from 26 Australian hospital liver clinics during 2016–2021 were followed up for 2 years. Risky alcohol use was defined by a combination of self‐report (≥40 g/day of ethanol), physician‐reported history of problematic alcohol use, and anti‐craving medication prescription via population‐based database linkage. We examined factors associated with advanced liver fibrosis and survival using multivariable logistic and Cox regression. Results: Among 1634 patients (62.3%) with risky alcohol use, 24.6% reported consuming ≥40 g/day of alcohol, 98.3% physician‐reported problematic alcohol use; only 4.1% were dispensed naltrexone/acamprosate. One hundred and forty‐three patients with cirrhosis reported ≥40 g/day of alcohol, 6 (4.3%) were prescribed naltrexone/acamprosate. Risky alcohol use was associated with advanced fibrosis (adjusted‐odds ratio 1.69, 95% confidence interval 1.32–2.17) and patients were over‐represented for cirrhosis (45.1% vs. 25.6% in no‐risky alcohol use [p < 0.001]) and hepatocellular carcinoma (5.7% vs. 2.5% [p < 0.001]). Sustained viral response (p = 0.319) and 2‐year survival (adjusted‐hazard ratio 1.98, 95% confidence interval 0.84–4.63) after DAA therapy were not associated with risky alcohol use. Discussion and Conclusions: Risky alcohol use in HCV patients was prevalent, but did not reduce HCV cure. Treatment for alcohol dependence was low. Risky alcohol use may be under‐recognised in liver clinics. Better integration of addiction medicine into liver services and increased resourcing and addiction medicine training opportunities for hepatologists may help address this. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Author

Lau, George, Yu, Ming-Lung, Wong, Grace, Thompson, Alexander, Ghazinian, Hasmik, Hou, Jin-Lin, Piratvisuth, Teerha, Jia, Ji-Dong, Mizokami, Masashi, Cheng, Gregory, Chen, Guo-Feng, Liu, Zhen-Wen, Baatarkhuu, Oidov, Cheng, Ann Lii, Ng, Woon Leung, Lau, Patrick, Mok, Tony, Chang, Jer-Ming, Hamid, Saeed, Dokmeci, A. Kadir, Gani, Rino A., Payawal, Diana A., Chow, Pierce, Park, Joong-Won, Strasser, Simone I., Mohamed, Rosmawaiti, Win, Khin Maung, Tawesak, Tanwandee, Sarin, Shiv Kumar, and Omata, Masao

Published
2021
Full Text
View/download PDF

14. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

Author

Ma, Haiyan, Lim, Tien Huey, Leerapun, Apinya, Weltman, Martin, Jia, Jidong, Lim, Young-suk, Tangkijvanich, Pisit, Sukeepaisarnjaroen, Wattana, Ji, Yun, Le Bert, Nina, Li, Dong, Zhang, Yao, Hamatake, Robert, Tan, Nicole, Li, Chunming, Strasser, Simone I., Ding, Huiguo, Yoon, Jung-Hwan, Stace, Nigel H., Ahmed, Tanvir, Anderson, Dave E., Yan, Li, Bertoletti, Antonio, Zhu, Qing, and Yuen, Man-Fung

Published
2021
Full Text
View/download PDF

15. Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia

Author

Wang, Dao Sen, primary, Phu, Amy, additional, McKee, Kristen, additional, Strasser, Simone I, additional, Sheils, Sinead, additional, Weltman, Martin, additional, Sellar, Sue, additional, Davis, Joshua S, additional, Young, Mel, additional, Braund, Alicia, additional, Farrell, Geoffrey C, additional, Blunn, Anne, additional, Harding, Damian, additional, Ralton, Lucy, additional, Muller, Kate, additional, Davison, Scott A, additional, Shaw, David, additional, Wood, Marnie, additional, Hajkowicz, Krispin, additional, Skolen, Richard, additional, Davies, Jane, additional, Tate-Baker, Jaclyn, additional, Doyle, Adam, additional, Tuma, Rhoda, additional, Hazeldine, Simon, additional, Lam, Wendy, additional, Edmiston, Natalie, additional, Zohrab, Krista, additional, Pratt, William, additional, Watson, Belinda, additional, Zekry, Amany, additional, Stephens, Carlie, additional, Clark, Paul J, additional, Day, Melany, additional, Park, Gordon, additional, Kim, Hami, additional, Wilson, Mark, additional, McGarity, Bruce, additional, Menzies, Natalie, additional, Russell, Darren, additional, Lam, Thao, additional, Boyd, Peter, additional, Kok, Jen, additional, George, Jacob, additional, and Douglas, Mark W, additional

Published
2024
Full Text
View/download PDF

16. Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia

Author

Nash, Emily, primary, Nicoll, Amanda, additional, Batt, Nicholas, additional, George, Jacob, additional, Perananthan, Varan, additional, Prince, David, additional, Wallace, Michael, additional, Gow, Paul, additional, Vaz, Karl, additional, Chitturi, Shivakumar, additional, Flores, Joan Ericka, additional, Braund, Alicia, additional, Bonnichsen, Mark, additional, Riordan, Stephen, additional, Humphris, Jeremy, additional, Duong, Tuan, additional, McKenzie, Catriona, additional, Liu, Ken, additional, and Strasser, Simone I., additional

Published
2024
Full Text
View/download PDF

17. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand

Author

Howell, Jess, Majumdar, Avik, Fink, Michael, Byrne, Mandy, McCaughan, Geoff, Strasser, Simone I., Crawford, Michael, Hodgkinson, Peter, Stuart, Katherine A., Tallis, Caroline, Chen, John, Wigg, Alan, Jones, Robert, Jaques, Bryon, Jeffrey, Gary, Adams, Leon, Wallace, Michael C., Gane, Ed, Thompson, Alex, and Gow, Paul

Published
2022
Full Text
View/download PDF

19. Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.

Author

Sim, Yu Ki, Chong, Ming Chuen, Gandhi, Mihir, Pokharkar, Yogesh Mahadev, Zhu, Yanan, Shi, Luming, Lequn, Li, Chen, Chien-Hung, Kudo, Masatoshi, Lee, Joon Hyeok, Strasser, Simone I., Chanwat, Rawisak, and Chow, Pierce K.H.

Subjects
HEPATOCELLULAR carcinoma, TREATMENT effectiveness, DIAGNOSIS, SPECTRUM allocation, HEPATITIS B, HEPATITIS C
Abstract

Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilized in clinical practice in the real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. Methods: Data were collected both retrospectively (planned 30% of the total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. Results: A total of 2,533 newly diagnosed HCC patients (1,052 in retrospective cohort and 1,481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia, and New Zealand, where the prevalence of hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension, and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stages, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, the presence of extrahepatic metastases or macrovascular invasion, and the use of subsequent lines of treatment were performed. Conclusion: The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs, and patient access to therapies may lead to wide geographical variations through the patient's treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care

Author

Clark, Paul J, primary, Valery, Patricia C, additional, Strasser, Simone I, additional, Weltman, Martin, additional, Thompson, Alex, additional, Levy, Miriam T, additional, Leggett, Barbara, additional, Zekry, Amany, additional, Rong, Julian, additional, Sinclair, Marie, additional, George, Jacob, additional, Bollipo, Steven, additional, McGarity, Bruce, additional, Sievert, William, additional, MacQuillan, Gerry, additional, Tse, Edmund, additional, Nicoll, Amanda, additional, Wade, Amanda, additional, Cheng, Wendy, additional, and Roberts, Stuart K, additional

Published
2023
Full Text
View/download PDF

22. Impact of Share 35 liver transplantation allocation in Australia and New Zealand

Author

Fink, Michael A., primary, Gow, Paul J., additional, McCaughan, Geoffrey W., additional, Hodgkinson, Peter, additional, Chen, John, additional, McCall, John, additional, Jaques, Bryon, additional, Crawford, Michael, additional, Strasser, Simone I., additional, Hardikar, Winita, additional, Brooke‐Smith, Mark, additional, Starkey, Graham, additional, Jeffrey, Gary P., additional, Gane, Ed, additional, Stormon, Michael, additional, Evans, Helen, additional, Tallis, Caroline, additional, Byrne, Amanda J., additional, and Jones, Robert M., additional

Published
2023
Full Text
View/download PDF

23. Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study

Author

Abdelmalak, Jonathan, primary, Strasser, Simone I., additional, Ngu, Natalie, additional, Dennis, Claude, additional, Sinclair, Marie, additional, Majumdar, Avik, additional, Collins, Kate, additional, Bateman, Katherine, additional, Dev, Anouk, additional, Abasszade, Joshua H., additional, Valaydon, Zina, additional, Saitta, Daniel, additional, Gazelakis, Kathryn, additional, Byers, Susan, additional, Holmes, Jacinta, additional, Thompson, Alexander J., additional, Pandiaraja, Dhivya, additional, Bollipo, Steven, additional, Sharma, Suresh, additional, Joseph, Merlyn, additional, Nicoll, Amanda, additional, Batt, Nicholas, additional, Sawhney, Rohit, additional, Tang, Myo J., additional, Lubel, John, additional, Riordan, Stephen, additional, Hannah, Nicholas, additional, Haridy, James, additional, Sood, Siddharth, additional, Lam, Eileen, additional, Greenhill, Elysia, additional, Majeed, Ammar, additional, Kemp, William, additional, Zalcberg, John, additional, and Roberts, Stuart K., additional

Published
2023
Full Text
View/download PDF

25. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Author

Lau, George, Yu, Ming-Lung, Wong, Grace, Thompson, Alexander, Ghazinian, Hasmik, Hou, Jin-Lin, Piratvisuth, Teerha, Jia, Ji-Dong, Mizokami, Masashi, Cheng, Gregory, Chen, Guo-Feng, Liu, Zhen-Wen, Baatarkhuu, Oidov, Cheng, Ann Lii, Ng, Woon Leung, Lau, Patrick, Mok, Tony, Chang, Jer-Ming, Hamid, Saeed, Dokmeci, A. Kadir, Gani, Rino A., Payawal, Diana A., Chow, Pierce, Park, Joong-Won, Strasser, Simone I., Mohamed, Rosmawaiti, Win, Khin Maung, Tanwandee, Tawesak, Sarin, Shiv Kumar, and Omata, Masao

Published
2022
Full Text
View/download PDF

27. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.

Author

Clark, Paul J, Valery, Patricia C, Strasser, Simone I, Weltman, Martin, Thompson, Alex, Levy, Miriam T, Leggett, Barbara, Zekry, Amany, Rong, Julian, Sinclair, Marie, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, MacQuillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Cheng, Wendy, and Roberts, Stuart K

Subjects
CHRONIC hepatitis C, HEPATITIS C, MENTAL illness, DRUG abuse, CONTINUUM of care, DRUG abuse treatment
Abstract

Background: Direct‐acting antiviral (DAA) therapies for hepatitis C virus infection (HCV) lead to excellent rates of sustained virological response (SVR). However, loss to follow‐up (LTFU) for SVR testing remains a challenge. We examine factors associated with LTFU in a real‐world setting. Methods: Adults who received DAA therapy for HCV in one of 26 centers across Australia during 2016–2021 were followed up for 2 years. Data sources included the patient medical records and the national Pharmaceutical and Medicare Benefits Schemes. Linkage to Medicare provided utilization data of other health‐care providers and re‐treatment with DAAs. LTFU was defined as no clinic attendance for SVR testing by at least 52 weeks after DAA treatment commencement. Multivariable logistic regression assessed factors associated with LTFU. Results: In 3619 patients included in the study (mean age 52.0 years; SD = 10.5), 33.6% had cirrhosis (69.4% Child–Pugh class B/C), and 19.3% had HCV treatment prior to the DAA era. Five hundred and fifteen patients (14.2%) were LTFU. HCV treatment initiation in 2017 or later (adj‐OR = 2.82, 95% confidence interval [CI] 2.25–3.54), younger age (adj‐OR = 2.63, 95% CI 1.80–3.84), Indigenous identification (adj‐OR = 1.99, 95% CI 1.23–3.21), current injection drug use or opioid replacement therapy (adj‐OR = 1.66, 95% CI 1.25–2.20), depression treatment (adj‐OR = 1.49, 95% CI 1.17–1.90), and male gender (adj‐OR = 1.31, 95% CI 1.04–1.66) were associated with LTFU. Conclusions: These findings stress the importance of strengthening the network of providers caring for patients with HCV. In particular, services targeting vulnerable groups of patients such as First Nations Peoples, youth health, and those with addiction and mental health disorders should be equipped to treat HCV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Impact of Share 35 liver transplantation allocation in Australia and New Zealand.

Author

Fink, Michael A., Gow, Paul J., McCaughan, Geoffrey W., Hodgkinson, Peter, Chen, John, McCall, John, Jaques, Bryon, Crawford, Michael, Strasser, Simone I., Hardikar, Winita, Brooke‐Smith, Mark, Starkey, Graham, Jeffrey, Gary P., Gane, Ed, Stormon, Michael, Evans, Helen, Tallis, Caroline, Byrne, Amanda J., and Jones, Robert M.

Subjects
ALLOCATION of organs, tissues, etc., LIVER transplantation, GRAFT survival, OVERALL survival, TREATMENT effectiveness
Abstract

Patients with high model for end‐stage liver disease (MELD) scores waiting for liver transplantation in Australia and New Zealand (ANZ) have had limited access to deceased donor livers and therefore binational sharing of livers, for patients with a MELD score ≥35 was introduced in February 2016. Waiting list mortality, post‐transplant outcomes and intention‐to‐treat survival were compared between patients whose MELD score reached 35 on the waiting list between October 2013 and April 2015 (Pre‐Share 35 group, n = 23) and patients who were Share 35 listed between February 2016 and May 2022 (Share 35 group, n = 112). There was significantly reduced waiting list mortality in share 35 listed patients in comparison to the pre‐Share 35 group (11.7% vs. 52.2%, OR.120 95% CI.044–.328, P <.001). Post‐transplant patient and graft survival were not significantly different between the groups (5‐year patient survival 82% vs. 84%, P =.991, 5‐year graft survival 82% vs. 76%, P =.543). Intention‐to‐treat survival was superior in the Share 35 group (HR.302, 95% CI.149–.614, P <.001). Introduction of Share 35 in ANZ resulted in a 78% risk reduction in waiting list mortality, equivalent post‐transplant survival and an improvement in intention‐to‐treat survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

Author

Thompson, Alexander J., primary, Jackson, Kathy, additional, Bonanzinga, Sara, additional, Hall, Sam A.L., additional, Hume, Simon, additional, Burns, Gareth S., additional, Sundararajan, Vijaya, additional, Ratnam, Dilip, additional, Levy, Miriam T., additional, Lubel, John, additional, Nicoll, Amanda J., additional, Strasser, Simone I., additional, Sievert, William, additional, Desmond, Paul V., additional, Ngu, Meng C., additional, Sinclair, Marie, additional, Meredith, Christopher, additional, Matthews, Gail, additional, Revill, Peter A., additional, Littlejohn, Margaret, additional, Bowden, D. Scott, additional, Canchola, Jesse A., additional, Torres, Jason, additional, Siew, Philip, additional, Lau, Jasmin, additional, La Brot, Benjamin, additional, Kuchta, Alison, additional, and Visvanathan, Kumar, additional

Published
2023
Full Text
View/download PDF

31. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Author

Puoti, Massimo, Foster, Graham R., Wang, Stanley, Mutimer, David, Gane, Edward, Moreno, Christophe, Chang, Ting Tsung, Lee, Samuel S., Marinho, Rui, Dufour, Jean-Francois, Pol, Stanislas, Hezode, Christophe, Gordon, Stuart C., Strasser, Simone I., Thuluvath, Paul J., Zhang, Zhenzhen, Lovell, Sandra, Pilot-Matias, Tami, and Mensa, Federico J.

Published
2018
Full Text
View/download PDF

32. Epidemiology, characteristics, and outcomes of patients with acute‐on‐chronic liver failure in Australia

Author

Chetwood, John David, primary, Sabih, Abdul‐Hamid, additional, Chan, Karen, additional, Salimi, Shirin, additional, Sheiban, Alexander, additional, Lin, Elton, additional, Chin, Simone, additional, Gu, Bonita, additional, Sastry, Vinay, additional, Coulshed, Andrew, additional, Tsoutsman, Tatiana, additional, Bowen, David G., additional, Majumdar, Avik, additional, Strasser, Simone I., additional, McCaughan, Geoffrey W., additional, and Liu, Ken, additional

Published
2023
Full Text
View/download PDF

35. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation

Author

Dennis, Claude, primary, Prince, David S., additional, Moayed-Alaei, Leila, additional, Remash, Devika, additional, Carr-Boyd, Emily, additional, Bowen, David G., additional, Strasser, Simone I., additional, Crawford, Michael, additional, Pulitano, Carlo, additional, Kench, James, additional, McCaughan, Geoffrey W., additional, McKenzie, Catriona, additional, and Liu, Ken, additional

Published
2022
Full Text
View/download PDF

36. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

Author

Maharaj, Ashika D., primary, Lubel, John, additional, Lam, Eileen, additional, Clark, Paul J., additional, Duncan, Oliver, additional, George, Jacob, additional, Jeffrey, Gary P., additional, Lipton, Lara, additional, Liu, Howard, additional, McCaughan, Geoffrey, additional, Neo, Eu‐Ling, additional, Philip, Jennifer, additional, Strasser, Simone I., additional, Stuart, Katherine, additional, Thompson, Alexander, additional, Tibballs, Jonathan, additional, Tu, Thomas, additional, Wallace, Michael C., additional, Wigg, Alan, additional, Wood, Marnie, additional, Zekry, Amany, additional, Greenhill, Elysia, additional, Ioannou, Liane J., additional, Ahlenstiel, Golo, additional, Bowers, Kaye, additional, Clarke, Stephen J., additional, Dev, Anouk, additional, Fink, Michael, additional, Goodwin, Mark, additional, Karapetis, Christos S., additional, Levy, Miriam T., additional, Muller, Kate, additional, O'Beirne, James, additional, Pryor, David, additional, Seow, James, additional, Shackel, Nicholas, additional, Tallis, Caroline, additional, Butler, Nick, additional, Olynyk, John K., additional, Reed‐Cox, Kate, additional, Zalcberg, John R., additional, and Roberts, Stuart K., additional

Published
2022
Full Text
View/download PDF

37. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways

Author

Hall, Samuel A L, primary, Burns, Gareth S, additional, Mooney, Benjamin J, additional, Millen, Rosemary, additional, Morris, Rachel, additional, Vogrin, Sara, additional, Sundararajan, Vijaya, additional, Ratnam, Dilip, additional, Levy, Miriam T, additional, Lubel, John S, additional, Nicoll, Amanda J, additional, Strasser, Simone I, additional, Sievert, William, additional, Desmond, Paul V, additional, Ngu, Meng C, additional, Angus, Peter, additional, Sinclair, Marie, additional, Meredith, Christopher, additional, Matthews, Gail, additional, Revill, Peter A, additional, Jackson, Kathy, additional, Littlejohn, Margaret, additional, Bowden, Scott, additional, Locarnini, Stephen A, additional, Thompson, Alexander J, additional, and Visvanathan, Kumar, additional

Published
2022
Full Text
View/download PDF

41. Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0

Author

Barreto, Savio G., primary, Strasser, Simone I., additional, McCaughan, Geoffrey W., additional, Fink, Michael A., additional, Jones, Robert, additional, McCall, John, additional, Munn, Stephen, additional, Macdonald, Graeme A., additional, Hodgkinson, Peter, additional, Jeffrey, Gary P., additional, Jaques, Bryon, additional, Crawford, Michael, additional, Brooke-Smith, Mark E., additional, and Chen, John W., additional

Published
2022
Full Text
View/download PDF

42. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

Author

Clark, Paul J., primary, Valery, Patricia C., additional, Strasser, Simone I., additional, Weltman, Martin, additional, Thompson, Alexander J., additional, Levy, Miriam, additional, Leggett, Barbara, additional, Zekry, Amany, additional, Rong, Julian, additional, Angus, Peter, additional, George, Jacob, additional, Bollipo, Steven, additional, McGarity, Bruce, additional, Sievert, William, additional, Macquillan, Gerry, additional, Tse, Edmund, additional, Nicoll, Amanda, additional, Wade, Amanda, additional, Chu, Geoff, additional, Harding, Damian, additional, Cheng, Wendy, additional, Farrell, Geoff, additional, and Roberts, Stuart K., additional

Published
2022
Full Text
View/download PDF

43. Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

Author

Hall, Samuel A. L., primary, Burns, Gareth S., additional, Anagnostou, Despina, additional, Vogrin, Sara, additional, Sundararajan, Vijaya, additional, Ratnam, Dilip, additional, Levy, Miriam T., additional, Lubel, John S., additional, Nicoll, Amanda J., additional, Strasser, Simone I., additional, Sievert, William, additional, Desmond, Paul V., additional, Ngu, Meng C., additional, Angus, Peter, additional, Sinclair, Marie, additional, Meredith, Christopher, additional, Matthews, Gail, additional, Revill, Peter A., additional, Jackson, Kathy, additional, Littlejohn, Margaret, additional, Bowden, D. Scott, additional, Locarnini, Stephen A., additional, Visvanathan, Kumar, additional, and Thompson, Alexander J., additional

Published
2022
Full Text
View/download PDF

44. Additional file 1 of Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, and Roberts, Stuart K.

Abstract

Additional file 1. Supplementary Table S1. List of Rx-Risk-V comorbidity categories with corresponding medicine groups and Anatomical Therapeutic Chemical (ATC), and ATC codes of medications dispensed to patients included in the Opera-C study. Supplementary Table 2. Prevalence of comorbidity categories included in the Rx-Risk-V according for First Nations Peoples and non-Indigenous Australians. Supplementary Table 3. Logistic regression analysis of factors associated with loss to follow-up among First Nations Peoples.

Published
2022
Full Text
View/download PDF

48. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.

Author

Hall, Samuel A L, Burns, Gareth S, Mooney, Benjamin J, Millen, Rosemary, Morris, Rachel, Vogrin, Sara, Sundararajan, Vijaya, Ratnam, Dilip, Levy, Miriam T, Lubel, John S, Nicoll, Amanda J, Strasser, Simone I, Sievert, William, Desmond, Paul V, Ngu, Meng C, Angus, Peter, Sinclair, Marie, Meredith, Christopher, Matthews, Gail, and Revill, Peter A

Subjects
CHRONIC hepatitis B, HEPATITIS B virus, TOLL-like receptors, MONONUCLEAR leukocytes, CELLULAR signal transduction, KILLER cells
Abstract

Background We evaluated the patterns of peripheral Toll-like receptor (TLR) signaling activity and the expression of TLRs and natural killer (NK) cell activation in a cohort of patients experiencing severe hepatitis flares after stopping nucleot(s)ide analogues (NAs) therapy. Methods Samples were collected longitudinally from patients with chronic hepatitis B who were enrolled in a prospective study of NA discontinuation. Patients experiencing hepatitis flares were compared with patients with normal alanine aminotransferase. Peripheral blood mononuclear cells (PBMCs) were stimulated with TLR ligands and cytokine secretion in the cell culture supernatant measured. Expression of TLR2/4, NKG2D, NKp46, and triggering receptor expressed on myeloid cells 1 (TREM-1) on monocytes, NK, and NK-T cells was measured. Results Seventeen patients with severe reactivation hepatitis flares were compared to 12 nonflare patients. Hepatitis flares were associated with increased activity of TLR2–8 and TLR9 signaling in PBMCs at the time of peak flare compared to baseline. Hepatitis flares were also associated with (1) upregulation of TLR2 and (2) TREM-1 receptor expression on NK. There were no differences at baseline between flare patients and nonflare patients. Conclusions Hepatitis flares off NA therapy have a significant innate inflammatory response with upregulation of TLR signaling on peripheral monocytes and TLR2 and TREM-1 expression on NK cells. This implicates the innate immune system in the immunopathogenesis of hepatitis B flares. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Australian consensus recommendations for the management of hepatitis B

Author

Lubel, John S, primary, Strasser, Simone I, additional, Thompson, Alexander J, additional, Cowie, Benjamin C, additional, MacLachlan, Jennifer, additional, Allard, Nicole L, additional, Holmes, Jacinta, additional, Kemp, William W, additional, Majumdar, Avik, additional, Iser, David, additional, Howell, Jess, additional, and Matthews, Gail V, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results